arrow
Y

Yasuhiro Asahina

Saitama Medical University
H指数:43
被引数:7,469

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Post-to Pretreatment Ratio of Serum CXCL10 Level Predicts Short-Term Liver Function Outcome in Compensated and Decompensated Cirrhotic Patients Due to Chronic Hepatitis C Virus Infection After Direct-Acting Antiviral Therapy

慢性丙型肝炎病毒感染患者直接抗病毒治疗后,血清CXCL10水平治疗后与治疗前的比值可预测代偿期和失代偿期肝硬化患者的短期肝功能结局

2026-02-010
OAAI
Corrigendum to “Peginterferon-alpha-2a add-on to treatment with siRNA JNJ-73763989 in virologically suppressed chronic hepatitis B: The phase II PENGUIN study” [JHEP Reports 2025 7(10) 101516]

勘误:“Peginterferon-alpha-2a add-on to treatment with siRNA JNJ-73763989 in virologically suppressed chronic hepatitis B: The phase II PENGUIN study” [JHEP Reports 2025 7(10) 101516]

2025-11-240
OAAI
Long non-coding RNA PWRN4 associated with post-SVR hepatocellular carcinoma: a genome-wide association study

长链非编码RNA PWRN4与术后SVR相关肝细胞癌:一项全基因组关联研究

2025-09-260
OAAI
Serum Growth Differentiation Factor 15 Can Be a Novel Biomarker to Predict the Prognosis of Patients With Hepatitis C Virus Cirrhosis After Virus Elimination

血清生长分化因子15可作为预测丙型肝炎病毒肝硬化患者病毒清除后预后的新型生物标志物

2025-09-180
OAAI
Crosstalk via ICAM-1 enhances supportive phenotype of stellate cells and drives hepatocyte proliferation in iPSC-derived hepatic organoids

通过ICAM-1的串扰增强了星状细胞的支持性表型,并驱动了iPSC源性肝类器官中的肝细胞增殖

2025-09-180
PREAI
Three-year overall survival in unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab

不可切除的肝细胞癌接受阿替利珠单抗联合贝伐珠单抗治疗后的三年总生存率

2025-08-280
PRE
Effect of Immunotherapy on Late Elderly Patients With Unresectable Hepatocellular Carcinoma: A Real-World Clinical Study

免疫疗法对不可切除肝癌晚期老年患者的影响:一项真实世界临床研究

2025-08-260
OAAI
Peginterferon-alpha-2a add-on to treatment with siRNA JNJ-73763989 in virologically suppressed chronic hepatitis B: the phase 2 PENGUIN study

聚乙二醇干扰素-α-2a联合siRNA JNJ-73763989治疗病毒学抑制的慢性乙型肝炎:PENGUIN二期研究

2025-07-090
OAAI
Posttreatment serum CXCL10 level stratifies survival in compensated and decompensated cirrhotic patients due to chronic hepatitis C virus infection after direct-acting antiviral therapy

治疗后血清CXCL10水平可对慢性丙型肝炎病毒感染导致的代偿期和失代偿期肝硬化患者的生存情况进行分层,尤其是在直接抗病毒治疗后。

2025-07-010
PRE
Pretreatment serum angiopoietin-2 predicts prognosis and liver functional reserve after successful HCV eradication with sofosbuvir and velpatasvir in patients with HCV-related decompensated cirrhosis

治疗前血清血管生成素-2可预测接受索磷布韦和韦帕他韦成功清除HCV后,HCV相关失代偿期肝硬化患者的预后及肝脏功能储备

2025-06-200
PRE
Elevated A2F bisect N-glycans of serum IgA reflect progression of liver fibrosis in patients with MASLD

升高的A2F平分N-糖苷酶在MASLD患者中反映肝纤维化的进展

2025-01-240
OA
Hepatitis B Virus-KMT2B Integration Drives Hepatic Oncogenic Processes in a Human Gene-edited Induced Pluripotent Stem Cells-derived Model
2025-01-010
OAAI
Factors involved in gastroesophageal varix-related events in patients with hepatitis C virus-related compensated and decompensated cirrhosis after direct-acting antiviral therapy
2024-10-290
OAAI
High serum gamma-glutamyltransferase level after hepatitis C virus elimination is a risk factor for the development of hepatocellular carcinoma
2024-07-291
PRE
Quantitative measurements of M2BPGi depend on liver fibrosis and inflammation
2024-04-167
PRE